MedNous article: A surprise finding in the clinic

Every once in a while a discovery in the clinic exceeds researchers’ expectations. This is what happened in early February 2022 when Vicore, received early data from a Phase 2 study of our candidate product, C21, for idiopathic pulmonary fibrosis (IPF).

Article published in MedNous (Vol 16, No 3, March 2022)

Read MedNous article in pdf

Back to news

Read more posts

Related posts

Idiopathic Pulmonary Fibrosis: 5 Things to Know

Report on the ATTRACT study

Patient insights to shape development of a dCBT for IPF patients

C21 shows promise against COVID-19 where other drugs have failed

Idiopathic Pulmonary Fibrosis (IPF) – weathering the pandemic